1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Bukwang Pharmaceutical Co., Ltd.

Bukwang Pharmaceutical Co., Ltd.

KKRX:003000
3,800.00
KRW
-65.00
(-1.68%)
79.72EPS
53.21P/E
422.28BMarket Cap
Bukwang Pharmaceutical Co., Ltd.
KRX:003000
(Korea Stock Exchange)

Recent

price

3,800.00

P/E

ratio

53.21

div

yld

- -

ROIC.AI

2011
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
2,276.59
1,352.57
1,918.83
1,692.11
1,854.6
1,838.66
1,789.08
2,019.71
3,199.96
2,159.19
2,270.81
2,376.41
2,549.8
1,690.28
2,170.32
2,429.5
1,970.8
Revenue per Share
345.28
85.6
214.77
252.69
309.12
325.21
204.02
148.6
2,400.01
-95.16
-96.41
-11.94
-33.05
-420.52
-35.81
152
80.43
Basic EPS, GAAP
260.11
400.76
611.92
415.02
321.79
72.61
-176.75
27.26
50.91
-363.47
-16.48
335.13
153.21
-163.71
430.43
124.31
-38.85
Free Cash Flow per Basic Share
166.3
173.63
67.6
173.71
184.52
191.46
294.44
240.4
141.88
125.47
163.16
81.06
91.43
- -
- -
59.71
- -
Dividend per Share
2,567.12
2,552.9
2,664.45
2,730.5
2,987.84
3,200.53
3,325.03
3,000.91
6,724.84
4,467.84
3,812.77
3,616.22
3,530.51
3,035.49
3,268.4
3,452.1
3,386.56
Book Value per Share
2,432.47
2,376.3
2,514.89
2,613.37
2,818.16
3,047.19
3,139.6
2,811.99
6,578.94
4,325.67
3,709.53
3,522.6
3,436.74
2,900.61
3,184.23
3,400.89
3,319.89
Tangible Book Value per Share
79
75
77
77
76
77
77
75
61
78
75
77
75
75
74
83
109
Basic Weighted Avg Shares
180,621
101,219
147,525
130,795
141,687
142,132
138,618
150,743
194,224
168,194
169,660
182,491
190,909
125,928
160,087
200,714
215,093
Sales/Revenue/Turnover
21.7
8.41
14.53
17.58
20.01
16.38
6.16
5.09
18.09
5.67
2.37
3.08
-0.12
-29.78
1.01
7.06
5.42
Operating Margin (%)
7,052
5,794
7,379
7,632
5,676
5,127
5,698
6,100
6,876
5,840
6,158
4,843
5,117
4,292
4,106
5,489
- -
Depreciation Expense
27,394
6,406
16,512
19,532
23,616
25,139
15,807
11,091
145,670
-7,412
-7,203
-917
-2,475
-31,330
-2,641
12,558
8,778
Net Income, GAAP
28.2
14.65
28.94
23.65
20.21
21.04
24.84
25.48
23.76
- -
- -
173.85
- -
- -
- -
- -
- -
Effective Tax Rate (%)
15.17
6.33
11.19
14.93
16.67
17.69
11.4
7.36
75
-4.41
-4.25
-0.5
-1.3
-24.88
-1.65
6.26
4.08
Profit Margin (%)
112,853
149,418
120,669
129,135
133,860
132,123
117,202
105,084
183,391
150,514
187,005
183,101
174,138
156,634
168,341
185,360
152,128
Working Capital
- -
40,000
- -
- -
- -
- -
- -
- -
- -
1,644
1,139
1,114
688
79,169
79,294
514
421
LT Debt
201,714
191,045
196,233
201,074
210,000
225,153
214,634
211,303
413,442
326,486
271,191
280,061
271,847
234,265
244,146
340,932
334,392
Total Equity
12.36
2.73
6.73
8.18
10.72
8.24
2.86
2.65
8.27
- -
- -
-1.42
- -
- -
- -
- -
- -
Return on Invested Capital (%)
13.06
3.21
8.02
9.47
11.49
11.55
7.19
5.21
46.64
- -
- -
-0.03
- -
- -
- -
- -
- -
Return on Capital (%)
13.92
3.26
8.53
9.83
11.49
11.55
7.19
5.21
46.64
-2
-2.46
-0.35
-0.93
-12.8
-1.12
4.3
3.01
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
79,827
80,119
80,246
LT Borrowings
- -
- -
- -
LT Finance Leases
514
535
421
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
99
99
99
Market Capitalization
373,446
720,252
422,285

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
303,177
299,689
266,353
Cash, Cash Equivalents & STI
216,208
209,423
169,096
Accounts Receivable, Net
27,845
26,813
30,839
Inventories
52,205
54,593
53,194
Total Current Liabilities
117,818
117,639
114,225
Payables & Accruals
- -
- -
- -
ST Debt
79,827
80,119
80,246
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.18%
6.08%
39.64%
Free Cash Flow
-439.91%
-576.06%
-67.65%
Net Income, GAAP
162.02%
116.33%
-575.43%
Sales/Revenue/Turnover
5.32%
6.13%
25.38%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34,393
36,915
42,597
46,181
160,087
2025
47,806
42,579
47,815
62,514
200,714
2026
47,776
56,988
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-25.71
-36.73
1.84
24.78
-35.81
2025
-0.92
94
11
47.32
152
2026
11.93
14
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
59.71
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bukwang Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company engaged primarily in the research, development, manufacturing, and marketing of innovative pharmaceutical products. Founded in 1960 and headquartered in Seoul, South Korea, Bukwang specializes in small molecule drugs across several therapeutic areas including central nervous system (CNS) disorders, metabolic diseases, oncology, immunology, and antiviral treatments. Its product portfolio includes prescription drugs such as LATUDA (lurasidone) for schizophrenia and bipolar depression; Levovir for chronic hepatitis B; Dexid for diabetic polyneuropathy; novel formulations for Parkinson’s disease dyskinesia (JM-010); and drugs targeting prostate cancer and immune disorders. The company also offers over-the-counter (OTC) products, health functional foods, and personal care items. In recent years, Bukwang has expanded its strategic focus on open innovation, combining its internal R&D capabilities with external partnerships and acquisitions. Notably, in 2021 it acquired Contera Pharma, a Danish biopharmaceutical company, to enhance its neurology pipeline, especially for the treatment of levodopa-induced dyskinesia in Parkinson’s disease with the asset JM-010. Further strategic development includes a significant investment partnership with OCI Company Ltd., a Korean energy and chemical enterprise, which acquired an 11% stake in Bukwang in 2022. This partnership aims to leverage OCI’s financial strength and Bukwang’s pharmaceutical expertise to accelerate R&D and expand its drug pipeline. Bukwang is also diversifying into advanced materials and environmental sectors such as semiconductors and secondary batteries, marking a significant operational expansion beyond pharmaceuticals. The company maintains extensive global connections through direct and indirect investments in more than 30 companies primarily in the U.S. and Europe. Bukwang continues to actively invest in R&D, focusing on innovative treatments ranging from CNS disorders, metabolic diseases, oncology to antiviral diseases, targeting global healthcare markets. It holds a distinguished position in Korea as one of the first companies with GMP certification and is recognized as an innovative pharmaceutical company for its R&D achievements and drug commercialization capabilities. Bukwang aims to sustain long-term growth by integrating new technologies and expanding its product pipeline through collaborations, joint ventures, and mergers and acquisitions.